KPV Research
KPV is the C-terminal tripeptide (lysine-proline-valine) of the alpha-melanocyte-stimulating hormone (α-MSH) sequence, studied in laboratory models for anti-inflammatory signaling and epithelial-cell biology. Distributed strictly as a research chemical.
Also known as: Lysine-Proline-Valine · α-MSH(11-13) C-terminal tripeptide
KPV represents the minimal active fragment of α-MSH responsible for much of its reported anti-inflammatory activity in laboratory systems. Research studies associate the tripeptide with downregulation of the NF-κB inflammatory signaling pathway and modulation of MAPK signaling, reducing pro-inflammatory mediator expression in cultured cells.
Mechanism of Action
As the C-terminal tripeptide of α-MSH, KPV retains the portion of the parent hormone most associated with anti-inflammatory signaling while lacking pigmentary activity. In cultured-cell studies, researchers report that KPV interferes with activation of NF-κB, a master transcriptional regulator of inflammatory gene expression, and modulates the MAPK cascade, collectively lowering production of pro-inflammatory cytokines and oxidative-stress markers. Because of its small size, the tripeptide is reported to enter cells directly and, in some intestinal-epithelium models, to be transported by peptide transporters. These mechanistic observations come entirely from in-vitro and experimental systems and are offered for scientific reference, not as evidence of any effect in humans.
Research Applications
KPV is examined in laboratory research on epithelial and immune-cell inflammation. Reported applications include intestinal-epithelium models of inflammatory signaling, keratinocyte studies of environmental-stress and apoptosis responses, and broader investigations of NF-κB and MAPK pathway modulation in cultured cells. It also appears in materials-science research, where it has been formulated into self-assembling peptide carriers for experimental delivery systems. This material is supplied for in-vitro and experimental-model experimentation only and is not intended for human or veterinary administration or for any diagnostic or treatment purpose.
Handling & Research Considerations
KPV is typically supplied as a lyophilized powder and prepared with sterile or bacteriostatic water for laboratory preparation, with stock and working solutions stored cold to maintain stability. As a short tripeptide it is comparatively soluble, but researchers should still confirm identity and purity by HPLC and mass spectrometry before experiments. Study designs should specify cell type, concentration range, and the inflammatory endpoints being measured to support reproducibility, since reported effects depend on model context. Results from cell and experimental systems should not be extrapolated to humans.
Applications at a glance
- NF-κB and MAPK inflammatory-pathway research in vitro
- Intestinal-epithelium inflammation models
- Keratinocyte oxidative-stress and apoptosis studies
- Peptide-carrier and delivery-system formulation research